218 related articles for article (PubMed ID: 12941723)
1. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study.
Winkler K; Konrad T; Füllert S; Friedrich I; Destani R; Baumstark MW; Krebs K; Wieland H; März W
Diabetes Care; 2003 Sep; 26(9):2588-94. PubMed ID: 12941723
[TBL] [Abstract][Full Text] [Related]
2. PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
Pfützner A; Schöndorf T; Tschöpe D; Lobmann R; Merke J; Müller J; Lehmann U; Fuchs W; Forst T
Diabetes Technol Ther; 2011 Jun; 13(6):637-43. PubMed ID: 21457065
[TBL] [Abstract][Full Text] [Related]
3. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes.
Lawrence JM; Reid J; Taylor GJ; Stirling C; Reckless JP
Diabetes Care; 2004 Jan; 27(1):41-6. PubMed ID: 14693964
[TBL] [Abstract][Full Text] [Related]
4. Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT study.
Leonhardt W; Pfützner A; Müller J; Pietzsch J; Forst T; Karagiannis E; Lübben G; Hanefeld M
Atherosclerosis; 2008 Nov; 201(1):155-62. PubMed ID: 18374336
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.
Rosenstock J; Einhorn D; Hershon K; Glazer NB; Yu S;
Int J Clin Pract; 2002 May; 56(4):251-7. PubMed ID: 12074206
[TBL] [Abstract][Full Text] [Related]
6. Low-density lipoprotein particle size, triglyceride-rich lipoproteins, and glucose tolerance in non-diabetic men with essential hypertension.
Rubies-Prat J; Ordóñez-Llanos J; Martin S; Blanco-Vaca F; Molina L; Goday A; Pedro-Botet J
Clin Exp Hypertens; 2001 Aug; 23(6):489-500. PubMed ID: 11478431
[TBL] [Abstract][Full Text] [Related]
7. Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study.
Füllert S; Schneider F; Haak E; Rau H; Badenhoop K; Lübben G; Usadel KH; Konrad T
J Clin Endocrinol Metab; 2002 Dec; 87(12):5503-6. PubMed ID: 12466345
[TBL] [Abstract][Full Text] [Related]
8. The role of pioglitazone in modifying the atherogenic lipoprotein profile.
Hanefeld M
Diabetes Obes Metab; 2009 Aug; 11(8):742-56. PubMed ID: 19519869
[TBL] [Abstract][Full Text] [Related]
9. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
Rosenblatt S; Miskin B; Glazer NB; Prince MJ; Robertson KE;
Coron Artery Dis; 2001 Aug; 12(5):413-23. PubMed ID: 11491207
[TBL] [Abstract][Full Text] [Related]
10. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.
Goldberg RB; Kendall DM; Deeg MA; Buse JB; Zagar AJ; Pinaire JA; Tan MH; Khan MA; Perez AT; Jacober SJ;
Diabetes Care; 2005 Jul; 28(7):1547-54. PubMed ID: 15983299
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of HMG-CoA reductase with cerivastatin lowers dense low density lipoproteins in patients with elevated fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus.
Scharnagl H; Winkler K; Mantz S; Baumstark MW; Wieland H; März W
Exp Clin Endocrinol Diabetes; 2004 May; 112(5):269-77. PubMed ID: 15146374
[TBL] [Abstract][Full Text] [Related]
12. Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes.
Tan MH; Johns D; Glazer NB
Clin Chem; 2004 Jul; 50(7):1184-8. PubMed ID: 15117857
[TBL] [Abstract][Full Text] [Related]
13. Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes.
Berneis K; Rizzo M; Stettler C; Chappuis B; Braun M; Diem P; Christ ER
Expert Opin Pharmacother; 2008 Feb; 9(3):343-9. PubMed ID: 18220486
[TBL] [Abstract][Full Text] [Related]
14. The metabolic basis of atherogenic dyslipidemia.
Vinik AI
Clin Cornerstone; 2005; 7(2-3):27-35. PubMed ID: 16473258
[TBL] [Abstract][Full Text] [Related]
15. Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients.
Hirano T; Yoshino G; Kashiwazaki K; Adachi M
Am J Hypertens; 2001 Sep; 14(9 Pt 1):908-13. PubMed ID: 11587157
[TBL] [Abstract][Full Text] [Related]
16. No improvement of high-density lipoprotein (HDL) vasorelaxant effect despite increase in HDL cholesterol concentration in type 2 diabetic patients treated with glitazones.
Perségol L; Duvillard L; Monier S; Brindisi MC; Bouillet B; Petit JM; Vergès B
J Clin Endocrinol Metab; 2014 Oct; 99(10):E2015-9. PubMed ID: 25137425
[TBL] [Abstract][Full Text] [Related]
17. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
Betteridge DJ; Vergès B
Diabetologia; 2005 Dec; 48(12):2477-81. PubMed ID: 16283239
[TBL] [Abstract][Full Text] [Related]
19. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome.
Szapary PO; Bloedon LT; Samaha FF; Duffy D; Wolfe ML; Soffer D; Reilly MP; Chittams J; Rader DJ
Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):182-8. PubMed ID: 16284192
[TBL] [Abstract][Full Text] [Related]
20. Serum lipoproteins improve after successful pharmacologic antidepressant treatment: a randomized open-label prospective trial.
Hummel J; Westphal S; Weber-Hamann B; Gilles M; Lederbogen F; Angermeier T; Luley C; Deuschle M; Kopf D
J Clin Psychiatry; 2011 Jul; 72(7):885-91. PubMed ID: 21294998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
